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For 100 years, efforts to detect and identify
microorganisms have generally begun with the
inoculation and incubation of growth media in the
laboratory. Colony purification and preparation of
limiting dilutions of liquid culture media have
provided at least two benefits: amplification of
microbial material and purification of single
organisms along with their direct descendants.
Because some microorganisms are not particular in
their growth requirements, these efforts have
yielded an array of diverse microbial cultivation
types. Serial propagation of microorganisms in the
presence of varied energy sources, analysis of their
macromolecular composition and their metabolic
by-products, and use of specific immunologic
reagents have created a variety of systems for
microbial classification and identification. Some
isolates purified from diseased tissues of animal
and human hosts produced identical disease when
injected into other, previously healthy hosts. By the
latter half of the 20th century, these findings had
led to optimism about our ability to detect and
recognize microscopic life forms, particularly forms
that can cause disease.
Microbial cultivation methods opened up an
unsuspected world of microscopic life and
presumed causative agents of human illness.
However, much of this world remained
uncharacterized. In the external environment,
certain biochemical activities could best be
explained by the presence of microorganisms,
although they could not be cultivated in vitro.
Sergei Winogradsky, a pioneering soil microbiolo-
gist of the early 20th century, spoke about the “less
docile” organisms that were not satisfied with
laboratory cultivation conditions. In the internal,
privileged niches of animals, microorganisms were
sometimes visualized in diseased tissues, and
persons with typical clinical signs of infection would
respond to antibiotics, despite unsuccessful efforts
at microbial propagation. That conserved genomic
sequences might be used to infer evolutionary
ancestry and be amplified directly from natural
sites of infection provided the framework for
cultivation-independent approaches for micro-
bial detection and identification. In a few years, it
became clear that most extant microorganisms in
the external environment had been completely
overlooked because of their resistance to
cultivation on artificial media.
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Features of a number of important but poorly explained human clinical syndromes
strongly indicate a microbial etiology. In these syndromes, the failure of cultivation-
dependent microbial detection methods reveals our ignorance of microbial growth
requirements. Sequence-based molecular methods, however, offer alternative
approaches for microbial identification directly from host specimens found in the setting of
unexplained acute illnesses, chronic inflammatory disease, and from anatomic sites that
contain  commensal microflora. The rapid expansion of genome sequence databases and
advances in biotechnology present opportunities and challenges: identification of
consensus sequences from which reliable, specific phylogenetic information can be
inferred for all taxonomic groups of pathogens, broad-range pathogen identification on the
basis of virulence-associated gene families, and use of host gene expression response
profiles as specific signatures of microbial infection.383 Vol. 4, No. 3, July–September 1998 Emerging Infectious Diseases
Special Issue
Sequence-Based Methods for Pathogen
Discovery
What features of a genetic sequence make it
useful for identifying uncharacterized micro-
organisms? (1). First, the sequence should be
conserved among a relatively large number of
known organisms. Second, its rate of change
should be constant over long periods and among
diverse organisms and should allow inferences of
evolutionary distance among a wide range of life
forms; the sequence should not be subject to widely
discrepant degrees of evolutionary pressure. Third,
the sequence should not have been shared among
different organisms by horizontal transmission.
Finally, the sequence should be amenable to broad-
range amplification or detection.
The sequence of the small subunit ribosomal
RNA or DNA (ssu rDNA), among other genomic
sequences, meets these criteria. Ssu rRNA
sequences were the first to reveal a tripartite tree
of cellular life, one that includes the bacteria,
archaea, and eukarya (2); few genetic sequences
reliably reflect the ancestry of such a wide array
of cellular life as the ssu rRNA. Since this
realization nearly two decades ago, a large ssu
rRNA sequence database has accumulated (3),
further enhancing the usefulness of this
particular locus. (More than 7,000 bacterial 16S
rDNA sequences are now available). Highly
conserved regions of the ssu rDNA and ssu rRNA
provide priming sites for broad-range polymerase
chain reaction (PCR) (or RT-PCR) and obviate the
need for specific information about a targeted
microorganism before this procedure. Thus, a
previously uncharacterized bacterium, for ex-
ample, can be identified from an infected site or
tissue by broad range bacterial 16S rDNA
amplification, sequencing, and phylogenetic
analysis (4). This approach was applied to the
uncultivated bacteria of bacillary angiomatosis in
1990 and of Whipple’s disease soon thereafter
(5,6). Because of the usual presence of host DNA,
eukaryotic pathogens (parasites, fungi) must be
approached either with domainwide primers and
partially purified pathogens or with range (e.g.,
kingdom)-restricted eukaryotic primers (7).
Broad-range PCR as a method for “pathogen
discovery” is not limited to ssu rDNA as a target
or to cellular life. Any phylogenetically reliable
family of orthologous gene sequences found
among a coherent group of microorganisms can
be targeted, as long as conserved priming sites
can be defined at sites that flank the informative
region of sequence. For example, a newly
discovered hantavirus was identified as a cause of
acute pulmonary disease by using broad-range
primers directed at a conserved region of a coat
protein-encoding genomic segment (8). A collec-
tion of family-restricted broad-range primers is
necessary to identify unrecognized viral patho-
gens; this collection is not yet comprehensive.
Two other independent sequence-based meth-
ods are available for pathogen discovery. One relies
upon subtractive hybridization to isolate fragments
of nucleic acid that are unique (different) to one
member of an otherwise matched pair of specimens;
these “difference” molecules are then selectively
amplified by using linker sequences that had been
ligated to all fragments derived from the infected
specimen. Multiple rounds of subtraction and
amplification are required to find rare fragments
within a complex common background. Although
better suited than differential display or suppres-
sive subtractive hybridization for low copy targets
and highly complex backgrounds (such as human
genomic DNA), this method, known as repre-
sentational difference analysis (RDA) (9), is labor-
intensive and cumbersome. Nonetheless, it identi-
fied for the first time the presumed causative agent
of Kaposi sarcoma, human herpesvirus 8 (9). RDA
enables detection of any class of microorganism;
however, it may be most useful for DNA viruses.
The third sequence-based pathogen discovery
method takes advantage of host immunologic
recognition of an exogenous microbial agent.
Immune sera are used to screen an expression
genomic library created from an infected
specimen. While laborious, this method has also
uncovered an important previously unrecognized
pathogen for humans: hepatitis C virus (10).
Sequence-based approaches take advantage
of the speed and sensitivity of rapidly evolving
molecular biologic methods and the specificity of
genotypic characterization. Consensus PCR has
the additional advantage of being able to target
families of sequences preselected for their
reliability in the inference of evolutionary
relationships. However, all approaches have
limitations. One of the most important for
sequence-based methods involves the processing
of clinical specimens. Difficulties include hetero-
geneity of sample, wide variation in the numbers
of microbial targets in any given sample,
resistance of some microorganisms to digestion
and subsequent release of nucleic acid, and
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and types—not to mention ubiquitous microbial
nucleic acid contamination of PCR reagents,
specimen collection materials, and externally
exposed surfaces of the host. These problems
reflect the intrinsic biologic variability of a highly
complex, partially characterized host. Standard-
ized procedures that produce consistent results
with large numbers of clinical specimens are rare.
Despite increasing attention to these issues,
particularly in the private and commercial
sectors, resource commitment and technology
advances have lagged behind the development of
methods for sequence acquisition and analysis. In
fact, it is far easier to generate a putative
microbial sequence from a clinical specimen than
it is to understand its clinical relevance.
As the process of pathogen discovery and
detection turns to the fundamental signature
macromolecules of all life forms and away from
reliance on cultivation, we increasingly rely on
our ability to understand a putative microorgan-
ism from its genetic sequence. Many families of
virulence-associated genes and gene products are
recognizable from their sequence, and their
targets are predictable. To predict whether the
microorganism whose presence is inferred from
amplified genomic fragments is the cause of the
disease under study, however, is far more
problematic. A replicating organism with which
to observe behavior (e.g., drug resistance) and
reproduce disease is not available. In fact, the
viability of the putative microorganism may not
be certain. Although detection of different
molecular markers (e.g., specific mRNAs, rRNA/
rDNA ratio, resistance-encoding loci) might help
resolve some of these questions, it is difficult to
determine whether these genotypes and markers
all derive from the same organism in that clinical
specimen. From a practical standpoint, proof of
disease causation from sequence-based investi-
gations will require data that address strength
and specificity of association, target dosage
effects, temporal considerations, response to
therapy, and use of in situ hybridization (11). The
selection of proper experimental and control
specimens is paramount.
Settings for Pathogen Discovery
Explorations of microbial diversity within the
external environment have yielded surprising
results. Nearly all bacteria and archaea revealed
by broad-range sequence “mining” in fresh water
sites, oceans, surface soils, and deep geologic
niches had not been recognized or ever cultivated in
the laboratory. Novel kingdoms of life have been
discovered with these genotypic methods (12,13). It
has been estimated that only 0.4% of all extant
bacterial species have been identified. Does this
remarkable lack of knowledge pertain to the subset
of microorganisms both capable and accomplished
in causing human disease? The molecular methods
described above could be applied in several settings
in which one might expect to find uncharacterized
microbial pathogens.
Acute, Life-Threatening Unexplained Illness
All clinicians are aware of cases character-
ized by sudden onset of fever, flu-like syndrome,
and hemodynamic instability, often accompanied
by leukocytosis or leukopenia and rapid
deterioration of one or more organ systems. In
some cases, despite the strong suggestion of a
microbial etiology, conventional diagnostic meth-
ods cannot determine the cause. The dramatic
nature of these illnesses belies their potential
importance to public health and their value in
revealing “emerging” agents of disease. An
Unexplained Deaths and Critical Illnesses
Project has been designed to identify and
characterize these illnesses (14). Laboratory
investigations include the application of broad-
range ssu rDNA PCR. RDA is planned for
carefully selected cases with matched control
samples. Appropriate specimens have been
obtained in only a minority of cases, but positive
results from cerebrospinal fluid samples are
encouraging. Two lessons have been learned. 1)
Well-recognized pathogens may be the cause of
some critical illnesses that cannot be explained
with traditional diagnostic methods. 2) The
process of clinical specimen selection and
collection may need to be rethought jointly by
molecular biologists and clinicians.
Chronic Idiopathic Disease
Adaptation and cooptation, features that
favor long-term survival of both participants,
dominate most host-pathogen relationships.
Persistent or intermittent inflammation indi-
cates host perturbation and a subtle imbalance to
the relationship and gives rise to clinical
manifestations. In fact, the epidemiologic,
clinical, and pathologic features of many chronic
inflammatory diseases are consistent with a
microbial cause, but intimate or symbiotic host-
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difficult to decipher and mimic in the laboratory.
Thus, it is not surprising that although microbial
etiologies are attractive hypotheses for many
chronic diseases, culture-dependent methods have
not produced much evidence. Serologic approaches
have been useful in providing some leads. For
example, the first clues of a possible chlamydial
etiology for coronary atherosclerosis were serologic
findings. Corroborating data then became available
from the use of molecular and in situ methods.
The list of chronic inflammatory diseases
with possible microbial etiologies is extensive
(15); it includes sarcoidosis, various forms of
inflammatory bowel disease, rheumatoid arthri-
tis, systemic lupus erythematosus, Wegener
granulomatosis, diabetes mellitus, primary
biliary cirrhosis, tropical sprue, and Kawasaki
disease. In this discussion, the concept of
pathogenic mechanism should be viewed broadly.
Many chronic diseases may result from damage
or disruption of local immunologic surveillance
systems by microbial infection or products; the
microorganism is subsequently cleared away, but
autoimmune responses or responses directed
against commensal flora persist. By the time
typical pathologic and clinical findings are
produced and the disease is recognized, the
inciting agent or its nucleic acids may be gone.
Under these circumstances, the optimal time for
specimen collection may be well before the disease
takes on its characteristic features. Clinical
suspicion, astute observation, and identification of
disease-predisposing factors are critical. Surpris-
ingly few published studies describe the application
of broad-range molecular pathogen discovery
methods to the diseases listed above or to other
enigmatic chronic disease syndromes. With the
finding of microbial sequences in these disease
settings, experimental criteria for identifying
disease causation must be rigorously pursued (11).
Commensal Microbial Flora
The human body harbors a 10-fold greater
number of microbial cells than human cells. The
commensal flora includes microorganisms that
occasionally cause disease, especially when host
defenses are impaired (due to immunosuppres-
sive drugs, disruption of anatomic barriers,
suppression of bacterial flora with antibiotics, or
insertion of artificial surfaces). However, in many
hosts with impaired conditions and signs and
symptoms of infectious disease, an etiologic agent
is not identified. If our understanding of
microbial diversity within the human-associated
commensal flora is as limited as it was of external
environments, these clinical observations may
not be surprising. That is, the inability to
cultivate some of the commensal flora may
explain the failure to diagnose related disease. In
addition to revolutionizing environmental micro-
biology, molecular methods may offer rewards for
clinical microbiology and the study of internal
environmental niches.
Recent research has compared culture-
dependent and culture-independent methods of
characterizing human commensal flora (16-19).
The results suggest that members of at least some
phylogenetic groups, e.g., the spirochetes, have
been ignored by traditional approaches. Direct
comparisons of these two methods will likely show
biases and deficiencies with each; nonetheless,
important aspects of microbial diversity will be
revealed by one and not the other. A complete
enumeration of complex microbial communities is
not the primary goal. Key members play crucial
roles in maintaining the health of the ecosystem
(20,21), and understanding community interac-
tions and function may be the more important goal.
Arthropod Vectors and Small Animal
Reservoirs
Several prominent, recently described culti-
vation-resistant pathogens are transmitted to
humans from small animal reservoirs through
airborne or vector-borne routes. These pathogens
include borreliae (22), bartonellae (23), ehrlichiae,
rickettsiae, babesiae, and hantaviruses. These
reservoirs and the relevant vectors are attractive
targets for pathogen discovery. Searches for
restricted groups of microorganisms, searches
within restricted host anatomic niches, or
searches that include subtractive or differential
techniques may be warranted, since all these
targets are also hosts for their own commensal
(e.g., intestinal) flora. Microorganisms that use
arthropod vectors often express different sets of
genes within vector versus animal host (e.g.,
human). Human immune recognition of differen-
tially expressed gene products might help
distinguish vector-associated pathogens from
nonpathogenic vector-associated flora.
Phylogenetic Diversity of Microbial
Pathogens
Nearly all kingdoms within the domain
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(Figure). Of those bacterial pathogens identi-
fied only by molecular methods, many are
clustered within some kingdoms and divisions,
such as the alpha-proteobacteria, which
include many organisms that form endosymbi-
otic relationships with their hosts.
Nearly all humans harbor in the intestinal
tract Archaea—among the most diverse and
numerous cellular life forms on earth (24)—most
notably methanogens. So why are there no known
archaeal pathogens? Although some of the most
well-known archaea were first identified in (and
were assumed to require) extreme environments,
they are also found in environments similar to
those found within the human body. However, in
vitro cultivation methods for many archaea are
unavailable, so how would we know if archaeal
pathogens existed? Molecular reagents for archaeal
detection and identification, i.e., rDNA-based
primers and probes, have not been systematically
applied to human disease-associated specimens.
Without such analyses, finding these organisms in
clinical samples would be unlikely.
Genomics and Newer Technologies
The ultimate genotype of a microorganism is
its complete genome sequence. Approximately 15
microbial genomes have been sequenced in their
entirety, and the rapid evolution of and large-
scale investment in DNA sequencing technology
predict full genome sequencing of approximately
50 microorganisms by the year 2000. This
massive infusion of primary sequence data
unleashes the potential to identify new families
of broadly conserved orthologous genes that could
be used to infer accurate phylogenies at every
level and sector of the evolutionary tree. The
number of completed genome sequences is too
small to effect this goal (25). The sequence data
sets for newly characterized genes are too small
to assess the reliability of the phylogenies they
predict. The problem imposed by horizontal gene
transfer is now more apparent with the analysis
of multitudes of gene families. To identify a well-
characterized microorganism, an exact genotypic
“hit” with a highly variable locus is sufficient.
Likewise, clonality and clone identification can
be determined with sequences from collections of
polymorphic, but conserved loci, e.g., “housekeep-
ing genes” (26). But for an unrecognized
organism, the sequence locus or loci selected for
genotyping must be highly conserved and
phylogenetically informative and reliable. Over
the next 5 years, with the increasing use of large-
scale comparative genomic techniques, microbial
sequence databases will represent the broad
diversity among distant ancestral relatives, as
well as the fine differences among closely related
cousins. Assessment of putative universal
sequences can be undertaken. All these develop-
ments and future trends apply equally well to the
wide array of animal viruses and viral genomes
(Table 1). As genotypes become more easily
interpreted, they will continue to displace
phenotypic characterization as the basis for
pathogen recognition.
Often the only difference between a
pathogenic and a nonpathogenic strain of the
same species, e.g., enteropathogenic and
nonenteropathogenic Escherichia coli, is a small
set of virulence genes. These differences are not
reflected in the ancestry inferred from more
stable chromosomal markers (Table 2). Yet
detection of these genes is a fundamental aspect
Figure. Evolutionary tree of the domain Bacteria
based upon comparative analysis of nearly complete
16S rDNA sequences.
Table 1. Newer diagnostic technologies
1. High-density DNA microarrays
• broad-based pathogen detection and
characterization: bacteria, eukarya, viruses
• virulence-associated gene families
• comprehensive host gene expression profiles
2. Improved nucleic acid subtractive methods
3. Novel bioassays for toxin activity
• neurons– or myocytes–on-a-chip387 Vol. 4, No. 3, July–September 1998 Emerging Infectious Diseases
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of pathogen identification. Microbial virulence is
a phenotype whose genetic basis is rapidly being
revealed. Families of virulence-associated genes
responsible for microbial adherence, toxicity,
specialized secretion, environmental sensing,
and subversion of immune defenses have been
defined, albeit with many sequence variations on
a theme (27,28). One of the most important features
of these genes is their proclivity toward horizontal
transfer and over relatively rapid time scales.
Genome sequencing efforts have facilitated, and
will continue to facilitate, this approach to pathogen
discovery. Physical clusters (or islands) of
virulence genes are being identified, and their
distinctive composition and boundaries are being
defined (29). One might well imagine the
development of a comprehensive set of consensus
primers and probes for detecting these gene
families, clusters, and islands (Table 1).
With increasing value placed on genotypic
information and increasing numbers of poten-
tially useful genotyping loci, the technology of
sequence determination and primary genomic
characterization has assumed center stage. Goals
include speed, convenience, and large-scale
sequencing. High density DNA microarray technol-
ogy is one of the most promising in this context
(Table 1). Depending on the format, microarrays
can be used to detect nucleic acid polymorphisms or
to sequence de novo; they can also quantitate
mRNA. At least two basic applications of DNA
microarray technology are available for pathogen
detection and identification; neither has been fully
developed or tested clinically (Table 1). The first
would consist of a set of probes designed to assess
ssu rDNA sequence diversity of all known
monophyletic groups of bacteria, archaea, viruses,
and nonanimal eukarya. Other phylogenetically
reliable loci might be substituted for rDNA or
included as well. In addition, consensus probes for
families of virulence-associated genes, as described
above, would facilitate identification of unsus-
pected or newly acquired pathogenic attributes in
organisms not usually associated with these traits.
Differential hybridizations and multiple
fluorophores allow easy detection of hybridized
target and normalization of quantified values to a
reference sample. This sort of broad-range
“pathogen detection chip” would identify mixed
infections, as well as chimeric or novel microorgan-
isms (Table 2); it could rapidly create an inventory
of highly complex microbial communities and
measure changes in individual members as a
function of varying environmental conditions.
The second theoretical use of DNA microarray
technology for pathogen detection would focus on
host gene responses. Arrays in current use at
academic and commercial research laboratories
are capable of quantitating expression responses
by 10,000 to 20,000 human genes simultaneously
(30-34). During most infectious diseases, directly
affected tissues, secondary sites, and circulating
leukocytes will likely display sets of common
nonspecific expression responses; however, since
each microbial pathogen interacts with and
manipulates the host in a complex and unique
manner, within these highly complex patterns
there will also likely be critical diagnostic
signatures that distinguish infection by one
pathogen from infection by another. Further-
more, these stereotypic expression patterns will
evolve. The time of initial host exposure to a
pathogen might be determined by comparing new
expression patterns with a suitable preexisting
set of timed profiles. Patterns will provide clues
about the pathogenesis of chronic inflammatory
disease (35). Through the identification of key
response genes might emerge novel diagnostic
assays for their putative protein products and
novel strategies for interfering with or blocking
disease pathogenesis.
In many cases, infection-associated tissue
damage occurs in the absence of intact
microorganisms. Toxin-mediated disease is a
prominent example. Often, microbial toxins act
at a distance from the original site of microbial
toxin production and release. In this setting,
genotypic approaches for microbial detection may
not be appropriate; in addition to the assessment
of host responses, novel bioassays for toxin
activity are attractive options (Table 1). For
example, in a system designed by Greg Kovacs at
Stanford University, neurons or myocytes are
cultivated on the electrical contacts of a
Table 2. Pathogens that may be difficult to detect or
identify
1. Pathogens that establish intimate relationships
with the host
• endosymbionts and intracellular organisms
2. Chimeras: natural versus man-made?
3. “Nonpathogens” that acquire virulence-associated
genes
4. Microorganisms without “universal” sequences?388 Emerging Infectious Diseases Vol. 4, No. 3, July–September 1998
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miniaturized circuit board. The electrical output
and properties of these cells can be monitored and
analyzed as they are exposed to diverse
membrane-active toxins. Although this technol-
ogy is at an early stage of development, we know
that such cells are extremely sensitive to
chemical toxins, and this sensitivity can be
recorded in the form of altered action potentials
and changes in impedance and cell movement.
Experiments are under way to test cell responses
to biologic toxins in a variety of clinically relevant
experimental conditions.
Relationships between Pathogen and Host
As more sensitive and comprehensive
methods for uncovering human-associated patho-
genic microorganisms identify previously unsus-
pected host-pathogen relationships, the nature of
these relationships may need to be rethought
(36,37). Parasitism and commensalism are
probably not the complete story; mutualism may
be more common in the human host than is
usually taught. Evidence of coevolution between
host and microbe suggests codependence. The
endosymbiont theory for the origin of eukaryotic
organelles is consistent with the same (38).
Microbial remnants and cryptic genomic frag-
ments may not be so uncommon within the
human genome; for example, approximately 1%
of the human genome is retrovirus sequence (39).
Some of these viral genes may be expressed
during local inflammation. The real challenges in
pathogen discovery will be the problems of
sequence interpretation, clinical relevance, and
proof of causation. In the end, pathogen discovery
will by necessity be a multidisciplinary effort (40).
Only with the coordinated interaction of epidemi-
ologists, pathologists, and clinicians will the role of
microorganisms in disease be clearly defined.
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